Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02179 瑞科生物 - B
Listing Date2022/03/31
Listing Price24.800
  • 21.700 +0.200 (+0.930%)    Sink Below Listing Price
  • 15-min delayed, last update: 24/03/2023 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    12 lot
  • One Lot Success Rate

Jiangsu Recbio Technology founded in 2012, it is a vaccine company dedicated to the research, development and commercialization of subunit vaccines. It primarily focuses on the R&D of HPV vaccine candidates.

The Group has established a vaccine portfolio consisting of 12 vaccine candidates, including its Core Product, REC603, a recombinant HPV 9-valent vaccine to prevent cervical cancer which is currently under phase III clinical trial.

In addition to REC603, the Group is also developing two recombinant HPV bivalent vaccine candidates, namely REC601 and REC602, targeting HPV 16/18 and HPV 6/11, respectively.

The Group is currently developing two COVID-19 vaccines. It was currently finalizing data analysis and clinical trial report in March 2022.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares30.85M H shares
No. of International Offer Shares27.77M H shares
No. of HK Offer Shares3.09M H shares
Offer Price$24.80
Stock Code2179
Sponsor(s)Morgan Stanley Asia Limited, CMB International Capital Limited, CLSA Capital Markets Limited
Application PeriodMar 21 (Mon) - noon, Mar 24 (Thu)
Price Determination Date--
Result Announcement DateOn or before Mar 30 (Wed)
Result Announcement DateOn or before Mar 30 (Wed)
Dealings in Shares commence onMar 31, 2022. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$24.80
NAV / share ($)$6.00 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 24.8, the net proceeds raised would be HKD 672.40M, of which
47.3% : research and development, manufacturing and commercialization of HPV vaccine pipeline
17.7% : for COVID-19 vaccine candidate ReCOV
21.1% : for remaining vaccine candidates
6.7% : strengthen R&D capabilities
7.2% : working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.